From RRMS to SPMS: research on DNA changes in blood during MS disease progression

From RRMS to SPMS: assessing whole blood DNA methylation signature - From RRMS to SPMS: assessing whole blood DNA methylation signature

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON61439

Enrollment

Registered

2026-04-29

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Multiple Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosed with RRMS and SPMS 18+ years old

Exclusion criteria

Exclusion criteria: Not an RRMS or an SPMS patient Younger than 18 years old

Design outcomes

Primary

Measure	Time frame
The main study parameter is the difference in whole blood DNA methylation between RRMS patients who progressed into SPMS stage compared to those with a stable RRMS disease course.	—

Countries

Netherlands

Contacts

Public ContactO Gerlach

Zuyderland

s.chenine@maastrichtuniversity.nl0644822772

Outcome results